<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940719</url>
  </required_header>
  <id_info>
    <org_study_id>MUMC09T43</org_study_id>
    <nct_id>NCT00940719</nct_id>
  </id_info>
  <brief_title>Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS)</brief_title>
  <official_title>The Effects of Vitamin D3 Supplementation on the T Cell Compartment in Multiple Sclerosis; a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orbis Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with Relapsing Remitting Multiple Sclerosis (RRMS), the investigators observed a
      positive correlation between regulatory T cell (Treg) function and vitamin D status. The
      present goal is to assess whether Treg function improves on supplementation with vitamin D3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In several studies, Multiple Sclerosis (MS) incidence and disease activity has been related
      with vitamin D status. We observed that RRMS patients who remained relapse free before blood
      collection had a better vitamin D status than patients who experienced relapses (Smolders et
      al. Mult Scler 2008;17:1220-1224). Since vitamin D3 is a potent promotor of T cell regulation
      in vitro (Smolders et al. J Neuroimmunol 2008;194:7-17), we hypothesised that a promotion of
      Treg function in MS patients might underlie its association with MS disease activity. In a
      cohort of RRMS patients, we observed a positive correlation of Treg function with vitamin D
      status (Smolders et al. PLoS ONE 2009;4:e6635). Furthermore, vitamin D status correlated
      positively with a Th1/Th2-balance which was more directed towards Th2. In the present study,
      we will assess whether treatment of RRMS patients with vitamin D3 promotes T cell regulation.

      In the present study, RRMS patients will be supplemented with vitamin D3, and regulatory T
      cell tests will be performed before and after supplementation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T cell regulation</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum 25-hydroxyvitamin D levels</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>calcium metabolism</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 1dd 500ug vitamin D3 for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>Oil-based solution, 1 dose of 500 microgram each day, during 3 months.</description>
    <arm_group_label>Vitamin D3</arm_group_label>
    <other_name>Vigantol Oil (Merck)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing Remitting MS (Revised MCDonald criteria 2005)

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  Progressive MS phenotype

          -  Abnormalities of vitamin D hormonal system other than low dietary intake or limited
             sun exposure

          -  Intake of drugs that influence vitamin D homeostasis other than corticosteroids

          -  Conditions with in increased susceptibility to hypercalcemia

          -  Alcohol or drug abuse

          -  Pregnancy or the intention to become pregnant within the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Hupperts, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Orbis Medical Center Sittard, Maastricht Univeristy Medical Center Maastricht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joost Smolders, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orbis Medical Center</name>
      <address>
        <city>Sittard</city>
        <zip>6130MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler. 2008 Nov;14(9):1220-4. doi: 10.1177/1352458508094399. Epub 2008 Jul 24.</citation>
    <PMID>18653736</PMID>
  </reference>
  <reference>
    <citation>Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol. 2008 Feb;194(1-2):7-17. doi: 10.1016/j.jneuroim.2007.11.014. Epub 2008 Jan 4. Review.</citation>
    <PMID>18177949</PMID>
  </reference>
  <reference>
    <citation>Smolders J, Thewissen M, Peelen E, Menheere P, Tervaert JW, Damoiseaux J, Hupperts R. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One. 2009 Aug 13;4(8):e6635. doi: 10.1371/journal.pone.0006635.</citation>
    <PMID>19675671</PMID>
  </reference>
  <reference>
    <citation>Smolders J, Menheere P, Thewissen M, Peelen E, Tervaert JW, Hupperts R, Damoiseaux J. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):243-6. doi: 10.1016/j.jsbmb.2010.03.001. Epub 2010 Mar 6.</citation>
    <PMID>20211254</PMID>
  </reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2009</study_first_posted>
  <last_update_submitted>August 10, 2010</last_update_submitted>
  <last_update_submitted_qc>August 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. dr. Raymond Hupperts, M.D., Ph.D.</name_title>
    <organization>Orbis Medical Center Sittard, Maastricht University Medical Center Maastricht</organization>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Regulatory T cell function</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Vitamin D3</keyword>
  <keyword>25-hydroxyvitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

